The top 10 companies in the Genome Editing

• Published Date: May 28, 2024

What is Genome Editing?

Genome editing, also called gene editing, is a combination of techs that permit experts to change a virus's DNA. Such technologies can add, eliminate, or change genetic material at precise locations in the genome.

Genome editing is a kind of genetic engineering that includes modifying, inserting, deleting, or swapping DNA in a living organism's genome. It varies from initial genetic engineering methods, which randomly insert genetic material into a host genome. Genome editing targets insertions to specific locations.

The genome editing industry size was USD 5,412.9 million in 2022, which will reach USD 20,397.8 million by 2030, observing a CAGR of 18.0% during the projection period.

Let's examine some leading firms within the genome editing industry

Merck KGaA

Establishment: 1668

Headquarters: Germany

Website: https:// www.merckgroup.com/en

Merck KGaA is a global science and technology company operating in healthcare, life sciences and business products. With a history of more than 360 years, Merck KGaA is known for developing innovative products and solutions in the pharmaceutical, biotechnology and specialty pharmaceutical sectors.

The company serves health professionals, researchers and entrepreneurs worldwide, with the goal of promoting scientific progress and sustainable development to improve human health and well-being.

Merck KGAA plays a leading role in genome editing, offering state-of-the-art technologies and tools that allow researchers to accurately sequence DNA In 2022, the company's total revenue reached approximately 22.2 billion euros.

Genscript Biotech Corporation

Establishment: 2002

Headquarters: U.S.

Website: https://www.merckgroup.com/en

GenScript is a global biotechnology company with more than 6,000 employees and a presence across multiple continents. They offer a range of products and services, including those in synthetic biology, immunology, and genome editing. They hold more than 200 patents and have contributed to more than 87,000 scientific papers. Their goal is to become the most trusted biotechnology company, with a focus on improving human and environmental health. GenScript’s revenue rose 27.7% to USD 625.7 million in 2022, compared to USD 490.1 million in 2021.

Integrated DNA Technologies Inc.

Establishment: 1987

Headquarters: U.S.

Website: https://www.idtdna.com/pages

IDT is important in the genome editing market, offering custom nucleic acids and CRISPR reagents. Their offerings include synthetic nucleic acids and genetic engineering to enable precision genome editing.

With a global presence in more than 100 countries in North America, Europe, Asia Pacific, and Latin America, IDT is a cornerstone for researchers and biotech companies worldwide Their access ensures sophisticated remediation technology genome reaches scientific communities, facilitating advances in healthcare, agriculture and biotech do

In 2023, Integrated DNA Technologies (IDT) reported revenues of USD 350 million, according to sources.

Agilent Technologies Inc.

Establishment: 1999

Headquarters: U.S.

Website: https://www.agilent.com/

Agilent Technologies, Inc. specifies laboratories, reagents and software for technical analysis, diagnostics and safety testing in areas such as food and pharmaceuticals.

Their product range includes mass spectrometry and microarray solutions, covering industries such as contract research facilities and pharmaceutical Agilent globally with sales offices and R&D centers around the world. Agilent Technologies Inc. posted 2023 revenues of $6.833 million.

Agilent’s tools in genome editing facilitate precision testing and research, supporting advances in biotechnology and healthcare. The company uses various sales channels including direct sales, distributors and e-commerce.

CRISPR Therapeutics AG

Establishment: 2013

Headquarters: Switzerland

Website: https://crisprtx.com/

CRISPR Therapeutics AG is a key player in Genome Editing, focusing on developing CRISPR/Cas9-based therapies for genetic disorders and cancer. The company operates globally, with a significant presence in the United States and Europe. In 2023, CRISPR Therapeutics reported a revenue of 371 million USD.

Their innovative technologies and research efforts contribute to advancements in healthcare, particularly in precision medicine. CRISPR Therapeutics' strategic collaborations and research initiatives reinforce its position as a leader in the field of genome editing, driving progress toward therapeutic breakthroughs worldwide.

Sangamo Therapeutics Inc.

Establishment: 1995

Headquarters: U.S.

Website: https://www.sangamo.com/

Sangamo Therapeutics Inc. Headquartered in California, USA, Sangamo has a global footprint, operating in North America, Europe and Asia Pacific.

Sangamo’s focus is on developing genomic modifying drugs to combat genetic diseases and oncology. Through a collaborative approach and innovative research, Sangamo continues to advance in precision medicine, offering promising solutions to patients around the world.

In July, the company signed a deal with Chroma Medicine to develop immunotherapies that use zinc-finger proteins (ZFP) to specifically recognize DNA sequences New England Biolabs Inc.

New England Biolabs (NEB)

Establishment: 1974

Headquarters: U.S.

Website: https://www.neb.com/en

Founded in 1974, New England Biolabs (NEB) supports scientific advancement, environmental stewardship, and philanthropy. Their profits enrich broad research programs, build relationships with clients, and drive scientific progress. NEB’s core values ​​of passion, humility, and authenticity shape its corporate culture. Offering a wide range of enzymes for genomic modification, including restriction enzymes, NEB products span PCR, gene expression, next-generation sequencing, biology produced, and so on

Priority was given to partnerships for technological expansion, especially in molecular diagnostics and nucleic acid vaccines. NEB’s commitment to research capacity extends to genome editing, providing the tools and expertise needed to drive innovation in this transformative field, helping scientists solve global challenges.

New England Biolabs has 350 employees, and the revenue per employee ratio is USD 122,857. New England Biolab's peak revenue was USD 43.0M in 2023.

Thermo Fisher Scientific Inc.

Establishment: 1956

Headquarters: U.S.

Website: https://www.thermofisher.com/in/en/home.html

Thermo Fisher Scientific, a leading scientific company, offers a wide range of products and services. With an income of about USD 40 billion annually, they are aimed at supporting their clients in scientific endeavors. This includes life science research, solutions analysis, laboratory efficiency, diagnostic testing, and the development of new treatments. Through their brands, they offer a comprehensive range of technologies, purchasing options, and pharmaceutical services.

Precision BioSciences Inc.

Establishment: 2006

Headquarters: U.S.

Website: http://www.precisionbiosciences.com

Precision BioSciences Inc. is a leading genome editing company, known for its proprietary ARCUS® platform for in vivo gene editing treatments. Based in North Carolina, USA, Precision operates globally and is present in key countries around the world. New precision technologies facilitate the precise modification of genes, such as insertions, deletions, and deletions, offering potential therapies for a variety of genetic diseases Their determination to promote genetic modification contributes to scientific progress, and meets important healthcare needs worldwide. In 2022, the company’s revenue will be USD 25.098 billion.